Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Patients with inflammatory bowel disease (IBD) have an increased risk of colon cancer. However, the immune cells and cytokines that mediate the transition from intestinal inflammation to cancer are poorly understood. We show that bacteria-induced colon cancer is accompanied by differential accumulation of IL-17(+)IL-22(+) colonic innate lymphoid cells (cILCs), which are phenotypically distinct from LTi and NK-22 cells, and that their depletion in mice with dysplastic inflammation blocks the development of invasive colon cancer. Analysis of the functional role of distinct Type 17 cytokines shows that although blockade of IL-17 inhibits some parameters of intestinal inflammation, reduction in dysplasia and colorectal cancer (CRC) requires neutralization of IL-22 indicating a unique role for IL-22 in the maintenance of cancer in this model. Mechanistic analyses showed that IL-22 selectively acts on epithelial cells to induce Stat3 phosphorylation and proliferation. Importantly, we could detect IL-22(+)CD3(+) and IL-22(+)CD3(−) cells in human CRC. Our results describe a new activity of IL-22 in the colon as a nonredundant mediator of the inflammatory cascade required for perpetuation of CRC, highlighting the IL-22 axis as a novel therapeutic target in colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although known to exert a tumor-promoting effect in colorectal cancer (Kirchberger et al., 2013; Wang et al., 2017)”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Kirchberger et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039 · cited 1×
“…in many mouse models (Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath…”
BackgroundThe risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959 · cited 1×
“In inflammatory bowel disease (IBD) patients, deranged inflammatory responses toward the intestinal microbiota increase the risk of colon cancer twofold (Eaden et al., 2001).”
BackgroundGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593 · cited 1×
“…(Hue et al., 2006; Izcue et al., 2008), and its components IL-23R and Stat3 are not only associated with IBD susceptibility (Duerr et al., 2006; Barrett et al., 2008) but also involved in inflammation-associated cancer in the skin and colon (Langowski et al., 2006; Bollrath et al., 2009;…”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 8×
“It is now appreciated that a Type 17 cytokine expression signature is not restricted to Th-17 cells, and that cytokines such as IL-17 and IL-22 can be produced by unconventional T cell populations and more recently described RORtexpressing innate lymphoid populations (Pearson et al., 2012).”
BackgroundInfluentialCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166 · cited 1×
“IL-22 may also promote cancer through direct effects on intestinal epithelial stem cells, previously shown to be key precursors for intestinal cancer (Barker et al., 2009).”
BackgroundGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155 · cited 2×
“The role of Stat3 in colon cancer is well known but this has been attributed to activation by IL-6 and IL-11 (Ernst et al., 2008; Grivennikov et al., 2009).”
BackgroundFusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundGenomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960 · cited 1×
“Furthermore, certain species like the anaerobic Fusobacterium nucleatum were found to be associated with human CRC tissue (Castellarin et al., 2012; Kostic et al., 2012).”
BackgroundInterleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., Abbas, A. R., Modrusan, Z., Ghilardi, N., de Sauvage, F. J., et al. (2008) · Nature Medicine · doi:10.1038/nm1720 · Cited by 1,921 · cited 8×
“IL-23 also drives colon cancer in an APC model, where it is induced in tumor-associated myeloid 928 Interleukin-22 in colon cancer | Kirchberger et al. (Reference numbers: 11/YH/0020 and 09/H0606/5) and informed written consent was given by all study patients.”
BackgroundInfluentialWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812 · cited 3×
“Th17 cell infiltration was also found in animal models of colon cancer, such as the ApcMin model driven by the enterotoxigenic bacterium Bacteroides fragilis, where blockade of IL-17 decreased tumor incidence (Wu et al., 2009).”
Background
Cited by
Items 101–200 of 529
Voigt, C., May, P., Gottschlich, A., Markota, A., Wenk, D., Gerlach, I., Voigt, S., Stathopoulos, G. T., Arendt, K. A. M., Heise, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705165114 · Cited by 151
“The cellular source of IL-22 in the tumor microenvironment varies according to the tumor entity and the species studied (1, 5).”
BackgroundA pathogenic role for T cell–derived IL-22BP in inflammatory bowel disease
Pelczar, P., Witkowski, M., Perez, L. G., Kempski, J., Hammel, A. G., Brockmann, L., Kleinschmidt, D., Wende, S., Haueis, C., Bedke, T., et al. (2016) · Science · doi:10.1126/science.aah5903 · Cited by 136
Balancing the innate immune system in tumor development
Hagerling, C., Casbon, A.-J., & Werb, Z. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.001 · Cited by 133
“IL-17+IL-22+ colonic ILCs produce IL-22 and their depletion in mice occludes development of colon cancer[84].”
IL-22 Fate Reporter Reveals Origin and Control of IL-22 Production in Homeostasis and Infection
Ahlfors, H., Morrison, P. J., Duarte, J. H., Li, Y., Biro, J., Tolaini, M., Di Meglio, P., Potocnik, A. J., & Stockinger, B. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401244 · Cited by 133
“, Salmonella), through suppression of related commensal bacteria (34), or the perpetuation of bacteria-induced colon cancer (35).”
BackgroundJones, G. W., & Jones, S. A. (2016) · Immunology · doi:10.1111/imm.12554 · Cited by 133
A Double Edged Sword Role of Interleukin-22 in Wound Healing and Tissue Regeneration
Arshad, T., Mansur, F., Pálek, R., Manzoor, S., & Liška, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02148 · Cited by 150
“Furthermore, by augmenting cellular proliferation and up-regulating inflammation, ILCs have proven to be essential in transitioning intestinal inflammation into colorectal cancer (148, 149).”
BackgroundRole of TH17 cytokines in the control of colorectal cancer
De Simone, V., Pallone, F., Monteleone, G., & Stolfi, C. (2013) · OncoImmunology · doi:10.4161/onci.26617 · Cited by 126
“In these mice, the antibody-mediated neutralization of IL-22 selectively decreases STAT3 activation in epithelial cells and reduces tumor burden.(56) Altogether, these observations are consistent with a recent findings suggesting an association between a genetic polymorphism in IL22 and an increased risk of developing…”
ResultInnate Immune Cells in Inflammation and Cancer
Nowarski, R., Gagliani, N., Huber, S., & Flavell, R. A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0081 · Cited by 144
“Likewise, ILC3 have been implicated in colorectal cancer (42), as discussed below.”
BackgroundRoles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer
Hurtado, C. G., Wan, F., Housseau, F., & Sears, C. L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.056 · Cited by 129
IL-17-Producing Cells in Tumor Immunity: Friends or Foes?
Kuen, D., Kim, B., & Chung, Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e6 · Cited by 134
“As such, blockade of IL-22 significantly lowered tumor formation in a mouse model of colon cancer (31), and IL-22 expressing tumorinfiltrating cells correlated with more advanced tumor severity and reduced survival in human cancers (31,100).”
BackgroundInfluentialEpigenetic modifications of the immune system in health and disease
Obata, Y., Furusawa, Y., & Hase, K. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2014.114 · Cited by 135
Aryl hydrocarbon receptor: Linking environment to immunity
Cella, M., & Colonna, M. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.10.002 · Cited by 119
“However, sustained and dysregulated IL-22 production becomes pathogenic and induce colitis and cancer [80, 81].”
BackgroundInnate lymphoid cells: new insights into function and development
Cortez, V. S., Robinette, M. L., & Colonna, M. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.004 · Cited by 117
Ruf, B., Greten, T. F., & Korangy, F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00562-w · Cited by 121
Diversity and function of group 1 innate lymphoid cells
Cortez, V. S., & Colonna, M. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.07.005 · Cited by 117
“Under certain conditions, ILC3s may also facilitate excessive intestinal inflammation and promote intestinal cancer (Kirchberger et al., 2013; Song et al., 2015).”
BackgroundHost–Bacterial Crosstalk Determines Staphylococcus aureus Nasal Colonization
Mulcahy, M. E., & McLoughlin, R. M. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.012 · Cited by 147
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 123
Luccia, B. D., Gilfillan, S., Cella, M., Colonna, M., & Huang, S. C. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180549 · Cited by 122
“Moreover, ILC3s cause gastrointestinal pathology in mouse models of IBD and cancer (Kirchberger et al., 2013; Song et al., 2015; Pearson et al., 2016).”
Microbiota and cancer: host cellular mechanisms activated by gut microbial metabolites
Tsvetikova, S. A., & Koshel, E. I. (2020) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2020.151425 · Cited by 119
A catch‐22: Interleukin‐22 and cancer
Hernández, P. P., Gronke, K., & Diefenbach, A. (2017) · European Journal of Immunology · doi:10.1002/eji.201747183 · Cited by 124
Activated innate lymphoid cell populations accumulate in human tumour tissues
Salimi, M., Wang, R., Yao, X., Li, X., Wang, X., Hu, Y., Chang, X., Fan, P., Dong, T., & Ogg, G. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4262-4 · Cited by 121
“to be the source of IL-17A and IL-22 and are found in higher frequencies in this model [16].”
InfluentialEmerging concepts and future challenges in innate lymphoid cell biology
Tait Wojno, E. D., & Artis, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160525 · Cited by 108
“, 2014), and IL-22–producing CD3− cells can be detected in human colorectal cancer (Kirchberger et al., 2013).”
BackgroundIL-22, cell regeneration and autoimmunity
Nikoopour, E., Bellemore, S. M., & Singh, B. (2014) · Cytokine · doi:10.1016/j.cyto.2014.09.007 · Cited by 112
RORγt, a multitask nuclear receptor at mucosal surfaces
Eberl, G. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.86 · Cited by 105
IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB
Victor, A. R., Nalin, A. P., Dong, W., McClory, S., Wei, M., Mao, C., Kladney, R. D., Youssef, Y., Chan, W. K., Briercheck, E. L., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601554 · Cited by 108
“Excess IL-22 production, which can be exacerbated by the presence of IL-18, can contribute to immune-mediated disease and cancer, likely through its tissue regenerative effects (13, 50).”
BackgroundRecruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
Bruchard, M., Geindreau, M., Perrichet, A., Truntzer, C., Ballot, E., Boidot, R., Racoeur, C., Barsac, E., Chalmin, F., Hibos, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01120-y · Cited by 106
STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?
Nguyen, P. M., Putoczki, T. L., & Ernst, M. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0225 · Cited by 108
Interleukin-22 promotes tumor angiogenesis
Protopsaltis, N. J., Liang, W. P., Nudleman, E., & Ferrara, N. (2018) · Angiogenesis · doi:10.1007/s10456-018-9658-x · Cited by 103
Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 133
“Interleukin 22 (IL-22) has been associated with resistance against chemotherapeutic drugs in patients with colorectal cancer [56] and tumorigenesis in CRC mouse models [57,58].”
BackgroundQi, J., Crinier, A., Escalière, B., Ye, Y., Wang, Z., Zhang, T., Batista, L., Liu, H., Hong, L., Wu, N., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100353 · Cited by 108
“In contrast, ILC3-derived IL-17 and IL-22 may contribute to gut cancer development.(23,24) There is, therefore, a clear need to investigate the presence and role of helper-like ILC subsets in various cancer indications.”
BackgroundVitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells
Kónya, V., Czarnewski, P., Forkel, M., Rao, A., Kokkinou, E., Villablanca, E. J., Almer, S. H., Lindforss, U., Friberg, D., Höög, C., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.045 · Cited by 103
Tschurtschenthaler, M., Wang, J., Fricke, C., Fritz, T. M. J., Niederreiter, L., Adolph, T. E., Sarcevic, E., Künzel, S., Offner, F. A., Kalinke, U., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305863 · Cited by 96
Group 3 Innate Lymphoid Cells: Communications Hubs of the Intestinal Immune System
Withers, D. R., & Hepworth, M. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01298 · Cited by 104
“Similarly, while ILC3-derived IL-22 is critical for supporting homeostatic intestinal barrier function, epithelial cell repair and regeneration, chronic overproduction of IL-22 by ILC3 may promote colorectal cancers (140, 141).”
BackgroundType 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis
Saranchova, I., Han, J. S., Zaman, R., Arora, H., Huang, H., Fenninger, F., Choi, K. B., Munro, L., Pfeifer, C. G., Welch, I. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20608-6 · Cited by 96
Xiong, D., Wang, Y., Singavi, A. K., Mackinnon, A. C., George, B., & You, M. (2018) · iScience · doi:10.1016/j.isci.2018.10.021 · Cited by 98
Autophagy, the innate immune response and cancer
Gerada, C., & Ryan, K. M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12774 · Cited by 106
A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis
Zhuang, Y., Cheng, P., Liu, X.-F., Peng, L.-S., Li, B.-S., Wang, T.-T., Chen, N., Li, W.-H., Shi, Y., Chen, W., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307020 · Cited by 96
Hemidesmosome integrity protects the colon against colitis and colorectal cancer
Arcangelis, A. D., Hamade, H., Alpy, F., Normand, S., Bruyère, E., Lefèbvre, O., Méchine‐Neuville, A., Siebert, S., Pfister, V., Lepage, P., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310847 · Cited by 106
Ning, C., Li, Y., Wang, Y., Han, G. C., Wang, R.-X., He, X., Li, X., Hou, C.-M., Ma, Y.-F., Sheng, D.-S., et al. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.18 · Cited by 97
Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs
Nussbaum, K., Burkhard, S., Ohs, I., Mair, F., Klose, C. S. N., Arnold, S. J., Diefenbach, A., Tugues, S., & Becher, B. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20162031 · Cited by 102
Innate lymphoid cells in intestinal immunity and inflammation
Bostick, J. W., & Zhou, L. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2055-3 · Cited by 103
“The risk for colon cancer development is associated with a genetic locus expressed in the hematopoietic compartment [183].”
BackgroundKim, S.-H., Cho, B.-H., Kiyono, H., & Jang, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-02729-6 · Cited by 91
Ganal-Vonarburg, S. C., & Duerr, C. U. (2019) · Immunology · doi:10.1111/imm.13138 · Cited by 102
Lo, B. C., Gold, M. J., Hughes, M. R., Antignano, F., Valdez, Y., Zaph, C., Harder, K. W., & McNagny, K. M. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8864 · Cited by 102
“This is likely through IL-22–dependent activation of epithelial progenitors (11), but ILC3s can also promote intestinal tumor formation in a chronic inflammatory setting (12).”
BackgroundColorectal carcinoma in the course of inflammatory bowel diseases
Hnatyszyn, A., Hryhorowicz, S., Kaczmarek-Ryś, M., Lis, E., Słomski, R., Scott, R. J., & Pławski, A. (2019) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-019-0118-4 · Cited by 97
Deng, Z., Mu, J., Tseng, M., Wattenberg, B., Zhuang, X., Egilmez, N. K., Wang, Q., Zhang, L., Norris, J., Guo, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7956 · Cited by 90
Liu, Y., Song, Y., Lin, D., Lei, L., Mei, Y., Jin, Z., Gong, H., Zhu, Y., Hu, B., Zhang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.050 · Cited by 97
An inducible circular RNA circKcnt2 inhibits ILC3 activation to facilitate colitis resolution
Liu, B., Ye, B., Zhu, X., Yang, L., Li, H., Liu, N., Zhu, P., Lu, T., He, L., Tian, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17944-5 · Cited by 86
Borowczak, J., Szczerbowski, K., Maniewski, M., Kowalewski, A., Janiczek-Polewska, M., Szylberg, A., Marszałek, A., & Szylberg, Ł. (2022) · Biomedicines · doi:10.3390/biomedicines10071670 · Cited by 99
Trabanelli, S., Curti, A., Lecciso, M., Salomé, B., Riether, C., Ochsenbein, A. F., Romero, P. J., & Jandus, C. (2015) · Haematologica · doi:10.3324/haematol.2014.119602 · Cited by 86
Tumino, N., Martini, S., Munari, E., Scordamaglia, F., Besi, F., Mariotti, F. R., Bogina, G. S., Mingari, M. C., Vacca, P., & Moretta, L. (2019) · International Journal of Cancer · doi:10.1002/ijc.32262 · Cited by 86
Activation and Suppression of Group 3 Innate Lymphoid Cells in the Gut
Zhou, W., & Sonnenberg, G. F. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.009 · Cited by 90
Perusina Lanfranca, M., Zhang, Y., Girgis, A., Kasselman, S., Lazarus, J., Kryczek, I., Delrosario, L., Rhim, A., Koneva, L., Sartor, M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.010 · Cited by 81
Koh, J., Kim, H. Y., Lee, Y., Park, I. K., Kang, C. H., Kim, Y. T., Kim, J.-E., Choi, M., Lee, W., Jeon, Y. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3458 · Cited by 86
B7-H1–expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets
Kuang, D.-M., Xiao, X., Zhao, Q., Chen, M.-M., Li, X.-F., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Wu, Y., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74381 · Cited by 82
Innate Lymphoid Cell-Epithelial Cell Modules Sustain Intestinal Homeostasis
Diefenbach, A., Gnafakis, S., & Shomrat, O. (2020) · Immunity · doi:10.1016/j.immuni.2020.02.016 · Cited by 88
Ho, G., Cartwright, J. A., Thompson, E. J., Bain, C. C., & Rossi, A. G. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa045 · Cited by 92
Immune-Epithelial Cross Talk in Regeneration and Repair
Guenin‐Macé, L., Konieczny, P., & Naik, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-062818 · Cited by 87
“A growing body of evidence also supports a role for IL-22 from Th17 cells and ILC3s in tumor development (153-155).”
BackgroundZhang, Q., Lou, Y., Bai, X., & Liang, T. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3500 · Cited by 87
Goverse, G., Labão‐Almeida, C., Ferreira, M., Molenaar, R., Wahlen, S., Konijn, T., Koning, J. J., Veiga‐Fernandes, H., & Mebius, R. E. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501106 · Cited by 94
“It was shown that uncontrolled IL-22 production can lead to the induction of tumor growth of intestinal epithelial cells, which can be suppressed by the production of IL-22 binding protein (31, 32).”
BackgroundDeciphering the Roles of Innate Lymphoid Cells in Cancer
Bruchard, M., & Ghiringhelli, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00656 · Cited by 79
“Bacteria induced colon cancer model shows an accumulation of ILCs where the depletion of IL-22 or CD90 reduced cancer development (61).”
BackgroundMicrobiota as a mediator of cancer progression and therapy
Pope, J. L., Tomkovich, S., Yang, Y., & Jobin, C. (2017) · Translational Research · doi:10.1016/j.trsl.2016.07.021 · Cited by 79
“Depletion of ILCs with anti-Thy1 or anti–IL-22 treatment reduced inflammation and tumors, suggesting a driving role for IL-22 producing ILC3s in H. hepaticus–induced CAC.99 Additional work suggests that ILC3-produced IL-22 promotes CAC by inducing epithelial cell proliferation and antimicrobial peptide production in a…”
InfluentialMima, K., Ogino, S., Nakagawa, S., Sawayama, H., Kinoshita, K., Krashima, R., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., et al. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.07.011 · Cited by 84
“TH 17 cells also produce IL22, which has been shown to promote colorectal tumor development and progression [78,79].”
BackgroundGiacomin, P., Moy, R. H., Noti, M., Osborne, L. C., Siracusa, M. C., Alenghat, T., Liu, B., McCorkell, K. A., Troy, A. E., Rak, G. D., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141831 · Cited by 83
“, 2013, 2015), and regulating epithelial cell homeostasis in health and disease (Ota et al., 2011; Sawa et al., 2011; Sonnenberg et al., 2011b; Hanash et al., 2012; Qiu et al., 2012; Kirchberger et al., 2013; Goto et al., 2014).”
BackgroundThe development of colitis in Il10 mice is dependent on IL-22
Gunasekera, D. C., Ma, J., Vacharathit, V., Shah, P. M., Ramakrishnan, A., Uprety, P., Shen, Z., Sheh, A., Brayton, C. F., Whary, M. T., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-019-0252-3 · Cited by 81
“Though ILC3s are an important early source of protective IL-22 (26), growing evidence in humans and mice suggests that chronic dysregulation of IL-22 and ILC3 responses in particular, results in intestinal pathology (14, 30, 70–75) and even tumorigenesis (76, 77).”
BackgroundDysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease
Forkel, M., & Mjösberg, J. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0652-3 · Cited by 80
Regulation of Innate Lymphoid Cells by Aryl Hydrocarbon Receptor
Li, S., Bostick, J. W., & Zhou, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01909 · Cited by 75
“Accordingly, IL-22-producing ILC3 are found to promote an experimental cancer model in mice (190).”
BackgroundColorectal cancer prevention: Immune modulation taking the stage
Fletcher, R., Wang, Y., Schoen, R. E., Finn, O. J., Yu, J., & Zhang, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.002 · Cited by 89
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., Halliwill, K., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 75
Group 3 innate lymphoid cells in intestinal health and disease
Horn, V., & Sonnenberg, G. F. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00906-3 · Cited by 88
“One early study in Rag1 –/– mice infected with H. hepaticus and administered with a carcinogen showed that ILC3-derived IL-22 promoted the progression of colitis-associated cancer 178 .”
Lo, B. C., Shin, S. B., Hernaez, D. C., Refaeli, I., Yu, H. B., Goebeler, V., Cait, A., Mohn, W. W., Vallance, B. A., & McNagny, K. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801308 · Cited by 85
“when epithelial cell hyperplasia is the underlying feature of pathology as is the case for colitis-associated cancer or psoriasis (13, 14).”
BackgroundInnate Lymphoid Cells (ILCs): Cytokine Hubs Regulating Immunity and Tissue Homeostasis
Nagasawa, M., Spits, H., & Ros, X. R. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a030304 · Cited by 72
“Interestingly, ILC3s, the major ILC subset in the gut, has been shown to promote tumor growth in a mouse model of bacteria-induced CRC in an IL-22-dependent manner (Kirchberger et al. 2013).”
BackgroundGpr109a Limits Microbiota-Induced IL-23 Production To Constrain ILC3-Mediated Colonic Inflammation
Bhatt, B., Zeng, P., Zhu, H., Sivaprakasam, S., Li, S., Xiao, H., Dong, L., Shiao, S.-Y. P. K., Kolhe, R. B., Patel, N., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701625 · Cited by 77
Helper-like Innate Lymphoid Cells in Humans and Mice
Guia, S., & Narni-Mancinelli, É. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.002 · Cited by 78
“IL-22 production can increase in human CRC tissues [120,121], and this cytokine can enhance tumor development and metastasis by activating STAT3 [121].”
BackgroundInnate lymphoid cells in inflammatory bowel diseases
Peters, C. P., Mjösberg, J., Bernink, J. H., & Spits, H. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.10.004 · Cited by 78
IL-17A–Induced PLET1 Expression Contributes to Tissue Repair and Colon Tumorigenesis
Zepp, J. A., Zhao, J., Liu, C., Bulek, K., Wu, L., Chen, X., Hao, Y., Wang, Z., Wang, X., Ouyang, W., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601540 · Cited by 70
Giannou, A. D., Kempski, J., Shiri, A. M., Lücke, J., Zhang, T., Zhao, L., Zazara, D. E., Cortesi, F., Riecken, K., Vesely, M. C. A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.014 · Cited by 74
The interplay between the microbiome and the adaptive immune response in cancer development
Russo, E., Taddei, A., Ringressi, M. N., Ricci, F., & Amedei, A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16635082 · Cited by 74
Extracellular Granzyme A Promotes Colorectal Cancer Development by Enhancing Gut Inflammation
Santiago, L., Castro, M., Pamplona, R. S., Garzón-Tituaña, M., Ramírez-Labrada, A., Tapia, E., Moreno, V. R., Layunta, E., Gil‐Gómez, G., Garrido, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107847 · Cited by 72
“The connection between inflammation and tumorigenesis is mediated by cells of the innate and adaptive immune system, including macrophages, eosinophils, innate lymphoid cells (ILCs), and specific subsets of CD4 T cells (Kirchberger et al., 2013; Lasry et al., 2016; Powell et al., 2017; Shalapour and Karin, 2015).”
BackgroundSignaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
Ternet, C., & Kiel, C. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00712-3 · Cited by 80
Fuchs, A. G., & Colonna, M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328365d339 · Cited by 70
TH17 Cell and Epithelial Cell Crosstalk during Inflammatory Bowel Disease and Carcinogenesis
Kempski, J., Brockmann, L., Gagliani, N., & Huber, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01373 · Cited by 67
“Although ILCs have been shown to promote tumor growth in mice through IL-22, data in humans indicate CCR6+ TH17 cells to be the major source (81, 82).”
BackgroundWang, C., Gong, G., Sheh, A., Muthupalani, S., Bryant, E. M., Puglisi, D. A., Holcombe, H., Conaway, E. A., Parry, N. A. P., Bakthavatchalu, V., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.9 · Cited by 66
“Previous studies have evaluated Hh-induced inflammatory changes within the lower bowel of RAG2-deficient mice at 6 weeks or longer following infection, or at 12 and 20 weeks post infection (WPI) in mice subsequently treated with AOM.(10,11,15) However, Hh-induced inflammatory changes at early time points following inf…”
BackgroundMethodResultInfluentialMicroenvironmental control of stem cell fate in intestinal homeostasis and disease
Biswas, S., Davis, H., Irshad, S., Sandberg, T., Worthley, D., & Leedham, S. (2015) · The Journal of Pathology · doi:10.1002/path.4563 · Cited by 66
“Neutralization of IL-22 signalling can attenuate and even reverse an inflammation-driven mouse model of colorectal cancer [59].”
BackgroundErmann, J., Staton, T., Glickman, J. N., de Waal Malefyt, R., & Glimcher, L. H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408540111 · Cited by 66
“Both protective and disease-promoting roles have been described for IL-22 in mouse IBD models (44–47), and it is feasible that IL-22 contributes to the development of colitis and colorectal carcinoma (48) in the TRUC model.”
BackgroundAryl hydrocarbon receptor: The master regulator of immune responses in allergic diseases
Riaz, F., Pan, F., & Wei, P. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057555 · Cited by 78
“However, IL-22 production that is persistent and dysregulated develops into a pathogen and causes colitis and cancer (211, 212).”
BackgroundRothenberg, M. E., Wang, Y., Lekkerkerker, A., Danilenko, D. M., Maciuca, R. D., Erickson, R., Herman, A. E., Stefanich, E. G., & Lu, T. T. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1164 · Cited by 71
“, xenografts of transformed human cell lines into immunocompromised mice), IL- 22 could promote epithelial tumor growth, including squamous cell and basal cell carcinoma(38) and colorectal cancer.(39,40) However, the translatability of these findings remains uncertain.”
BackgroundFrigerio, S., Lartey, D. A., D’Haens, G., & Grootjans, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312739 · Cited by 69
“Further mechanistic analyses showed that IL-22 produced by colonic ILC3s in CAC mice acts on IECs to induce STAT3 phosphorylation [212].”
BackgroundThe role of commensal bacteria in the regulation of sensitization to food allergens
Cao, S. Z., Feehley, T., & Nagler‐Anderson, C. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.026 · Cited by 71
“In addition to increasing the expression of antimicrobial peptides, IL-22 is known to promote IEC proliferation [69,70] and mucus secretion by goblet cells [71].”
BackgroundGastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings
Barral, M., Dohan, A. J. J., Allez, M., Boudiaf, M., Camus, M., Laurent, V., Hoeffel, C. C., & Soyer, P. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.005 · Cited by 69
Bergmann, H., Roth, S., Pechloff, K., Kiss, E. A., Kuhn, S. P., Heikenwälder, M. F., Diefenbach, A., Greten, F. R., & Ruland, J. (2017) · European Journal of Immunology · doi:10.1002/eji.201646765 · Cited by 71
Montalban‐Arques, A., Chaparro, M., Gisbert, J. P., & Bernardo, D. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy177 · Cited by 73
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 67
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse
Manjili, S. H., Isbell, M., Ghochaghi, N., Perkinson, T., & Manjili, M. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.023 · Cited by 63
Beyond NK Cells: The Expanding Universe of Innate Lymphoid Cells
Cella, M., Miller, H., & Song, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00282 · Cited by 59
“Accordingly, recent evidence has linked colonic ILC3s to colon cancer in a genetically prone bacterial-driven model of colon cancer (80).”
BackgroundHow Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis, M., Duruisseaux, M., Brevet, M., & Dumontet, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00492 · Cited by 65
Chronic inflammation and the development of malignancy in the GI tract
Fichtner‐Feigl, S., Kesselring, R., & Strober, W. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.007 · Cited by 63
Gwela, A., Siddhanathi, P., Chapman, R. W., Travis, S. P. L., Powrie, F. M., Arancibia-Cárcamo, C. V., & Geremia, A. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx050 · Cited by 58
“5 [167–607] Thrombocytopenia, n [%] < 150*109/l 0 [0] Liver cirrhosis, n [%] 1 [3] IBD duration, years median [range] 14 [3–43] 9 [0–46] IBD extent Extensive, n [%] 22 [69] 9 [26] Left-sided, n [%] 3 18 [53] Proctitis, n [%] 0 [0] 6 [18] Previous colectomy, n [%] 7 [22] 1 [3] UCEIS 0–2, n 8 7 3–5, n 4 2 6–8, n 0 0 Inf…”
Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis
Simone, V. D., Ronchetti, G., Franzè, E., Colantoni, A., Ortenzi, A., Fantini, M. C., Rizzo, A., Sica, G. S., Sileri, P., Rossi, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3532 · Cited by 60
The balance of power: innate lymphoid cells in tissue inflammation and repair
Castellanos, J. G., & Longman, R. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124617 · Cited by 57
Metadata
- Authors
- Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F.
- Affiliations
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Corresponding author
- Powrie, Fiona
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-04-15
- Volume
- 210
- Issue
- 5
- Pages
- 917-931
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3646494
- OpenAlex
- W2124499950
- Cited by
- 529
- References
- 52
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 24 · 2023: 33 · 2022: 39 · 2021: 34 · 2020: 54 · 2019: 51 · 2018: 42 · 2017: 55 · 2016: 48 · 2015: 54 · 2014: 50 · 2013: 12
- FWCI
- 30.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Royal College of Pathologists of Australasia
- Wellcome Trust (095688/Z/11/Z, 095688)
- Cancer Research UK (A7297, A11663)
- National Institute for Health and Care Research
- European Commission (223151)
- Jean Shanks Foundation
- Austrian Science Fund
- Genentech
- Biotechnology and Biological Sciences Research Council (BB/I005609/1)
- NIHR Oxford Biomedical Research Centre
- UCB Celltech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- colon cancer, IL-22, IL-17, innate lymphoid cells, inflammatory bowel disease, STAT3 phosphorylation, epithelial cell proliferation, therapeutic target
- MeSH terms
- Interleukin-22, Animals, Antigens, Ly, Cell Transformation, Neoplastic, Colitis, Colon, Colonic Neoplasms, Disease Models, Animal, Epithelial Cells, Humans, Interleukins, Lymphocytes, Phosphorylation, CD4 Antigens, Gene Expression Regulation, Neoplastic, Helicobacter, Disease Progression, Cell Lineage, STAT3 Transcription Factor, Mice, Natural Cytotoxicity Triggering Receptor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.